FDA Roundtable: E-Cigs Get Bureaucratic Ear
Published Date: 12/29/2025
Notice
Summary
The FDA is hosting a roundtable on February 10, 2026, to hear from small makers of electronic nicotine delivery systems (like e-cigarettes) about their experiences with the premarket approval process. They want to improve how these products are reviewed, focusing on safety, manufacturing, and health effects. If you’re involved in making or selling these products, now’s the time to share your thoughts and help shape future rules!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA Roundtable for Small ENDS Makers
The FDA is holding a roundtable on February 10, 2026 to hear from small electronic nicotine delivery systems (ENDS) manufacturers about PMTA (premarket tobacco product application) submissions. Topics include product characterization, manufacturing controls, pharmacological profile (e.g., pharmacokinetic studies), studies of adult benefit (e.g., longitudinal cohort/RCT studies), and toxicological profile (e.g., estimated lifetime cancer risk).
Limited Panel Slots and Eligibility Rules
Registration to participate as a panelist is open to "small tobacco product manufacturers" (those with fewer than 350 employees) and is limited to 30 participants representing companies that have previously submitted an ENDS PMTA, including pending PMTAs. Registration is free and panelist registration must be submitted by January 27, 2026, 11:59 p.m. Eastern Time; only one person may represent each company and final eligibility is determined by FDA.
Public Docket, Comment Deadlines, and Remote Access
FDA established a public docket (Docket No. FDA-2025-N-7022) beginning December 29, 2025 for comments on the roundtable topics; electronic comments to be considered for the roundtable must be submitted by February 3, 2026, and all other electronic comments must be submitted by March 12, 2026 (regulations.gov will accept comments through 11:59 p.m. Eastern Time on March 12, 2026). The FDA accepts confidential written submissions under a two-copy process, will provide virtual viewing of the roundtable, and will post a transcript to regulations.gov when available; requests for disability accommodations must be emailed by February 3, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-23843, System Energy Resources Inc.; Grand Gulf Site Early Site Permit; Early Site Permit Renewal Application
System Energy Resources Inc., part of Entergy, wants to extend their Grand Gulf nuclear site permit for 20 more years beyond April 2027. They’ve asked the Nuclear Regulatory Commission to renew the permit without updating all the old info. This means the site can keep moving forward without big delays or extra costs right now.
Next: 2025-23852, Over-the-Counter Monograph Drug User Fee Amendments-OTC Monograph Order Request Fee Rates for Fiscal Year 2026
Starting October 1, 2025, companies that make or request orders for over-the-counter (OTC) drugs will pay new fees to the FDA for fiscal year 2026. These fees help the FDA keep OTC drugs safe and effective. If you’re a manufacturer or submitter, get ready for updated costs that will last through September 30, 2026.